Ernakulam Court Summons Ramdev, Balkrishna In Drug Promotion Case

THIRUVANANTHAPURAM:  A court in Ernakulam has directed Baba Ramdev and Acharya Balkrishna of Divya Pharmacy to be present in the court in cases filed by the Drugs Control Department. The Judicial First Class Magistrate Court in Kakkanad issued two separate orders in connection with the illegal drug promotions.

The department accused both Ramdev and Acharya of violating Section 3(d) of Drugs and Magic Remedies (Objectionable Advertisements) Act in these cases. The court issued summons to the accused in one case on January 30 and issued directions for the production of the accused in another case on February 17 next year. Besides, the Additional Chief Judicial Magistrate in Thiruvananthapuram also issued notice to the same accused in another case filed by the department. The case is posted for November 21.

The Drugs Control Department has filed a total of 10 cases against Ramdev-promoted Divya Pharmacy for publishing misleading advertisements in various courts in Kozhikode (4 cases), Palakkad (3 cases), Ernakulam (2 cases) and Thiruvananthapuram (1 case).

The cases have been registered for violation of Section 3(d) of Drugs and Magic Remedies (Objectionable advertisement) Act 1954. Under the law, cure of 54 diseases listed in the schedule should not be advertised.

The state’s drugs control department became the first drug licensing agency in the country to file a case against Patanjali Ayurved in a court for publishing misleading advertisements in April.

The department found that Patanjali’s Divya Pharmacy advertised pharmaceutical products for diseases, in which the cure should not be advertised, in more than 30 instances. The cases were initiated based on a complaint filed by Dr Babu K V, a health activist from Kannur.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit